Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 06 2022 - 4:23PM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global
biopharmaceutical company and leader in complement, today announced
that the company approved the grant of equity awards to four new
employees with a grant date of May 2, 2022, as equity inducement
awards outside of the company's 2017 Stock Incentive Plan (but
under the terms of the 2022 Inducement Stock Incentive Plan) and
material to the employees’ acceptance of employment with the
company. The equity awards were approved in accordance with Nasdaq
Listing Rule 5635(c)(4).
The employees received options to purchase 19,031 shares of
Apellis common stock and 23,332 restricted stock units (RSUs). The
options have an exercise price of $44.96, which is equal to the
closing price of Apellis common stock on May 2, 2022, the grant
date of the options. One-fourth of the shares underlying the
employee options will vest on the one-year anniversary of the grant
date and thereafter 1/48th of the shares underlying the employee
options will vest monthly, such that the shares underlying the
options granted to the employees will be fully vested on the fourth
anniversary of the grant date, subject to the employees’ continued
employment with Apellis on such vesting dates. Each RSU will vest
as to 25% of the shares underlying the RSU award on the first
anniversary of the grant date and as to an additional 25% of the
shares underlying the RSU award annually thereafter, subject to
each such employee's continued employment on each vesting date.
About ApellisApellis Pharmaceuticals, Inc. is a
global biopharmaceutical company that is committed to leveraging
courageous science, creativity, and compassion to deliver
life-changing therapies. Leaders in complement, we ushered in the
first new class of complement medicine in 15 years with the
approval of the first and only targeted C3 therapy. We are
advancing this science to continually develop transformative
medicines for people living with rare, retinal, and neurological
diseases. For more information, please
visit http://apellis.com or follow us
on Twitter and LinkedIn.
Apellis Forward-Looking StatementStatements in
this press release about future expectations, plans and prospects,
as well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements regarding timing of anticipated regulatory submissions.
The words “anticipate,” “believe,” “continue,” “could,” “estimate,”
“expect,” “intend,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “target,” “will,” “would” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, as discussed in the “Risk Factors” section of
Apellis’ Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on May 4, 2022 and the risks described in
other filings that Apellis may make with the Securities and
Exchange Commission. Any forward-looking statements contained in
this press release speak only as of the date hereof, and Apellis
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
Investor Contact:Meredith
Kayameredith.kaya@apellis.com 617.599.8178
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Sep 2023 to Sep 2024